ROP treatment proves its worth

Article

Intravenous administration of IPLEX, Insmed Inc's rhIGF-I/rhIGFBP-3 complex, is well-tolerated and efficacious in significantly premature infants, according to Phase I study results announced at this year's European Society for Paediatric Endocrinology meeting, held 20?23 September in Istanbul, Turkey.

Intravenous administration of IPLEX, an rhIGF-I/rhIGFBP-3 complex, is well-tolerated and efficacious in significantly premature infants for the treatment of retinopathy of prematurity (ROP), according to Phase I study results announced at this year's European Society for Paediatric Endocrinology meeting, held 20–23 September in Istanbul, Turkey.

IPLEX's combination of recombinant human insulin-like growth factor (rhIGF-I) with its predominant binding protein IGFBP-3 (rhIGFBP-3) is designed to treat ROP by increasing to normal the low serum levels of the protein IGF- I in low-birth-weight premature neonatal subjects.

The open-label study evaluated the effect of the treatment on infants born between 26 weeks + 0 days and 29 weeks + 1 day of gestation (n=5). Birth weight ranged from 810 to 1310 g, and all subjects received an intravenous dose of IPLEX three days after birth. In all subjects, serum levels of IGF-I were raised to within the normal physiological range for non-premature infants. No acute adverse events were noted.

The developers of IPLEX, plans to initiate a Phase II multicentre study before the end of the year. If found to be safe, well-tolerated and clinically effective, IPLEX may offer a more effective ROP treatment option than current methods, which tend to be highly invasive and focus only on arresting disease progression rather than reversing previous damage.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.